Jefferson University Hospitals

Provider Profile

Takami Sato, MD, PhD

Jefferson University Physician

Academic Title: Professor
Director, Metastatic Uveal Melanoma Program

Medical Oncology
Medical Oncology - Uveal Melanoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340
Bodine Center
111 S. 11th Street
Philadelphia PA 19107
Phone: (215) 503-3158
Fax: (215) 955-9600

Medical Services

Board Certifications

  • Pediatrics

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Best Doctors in America 2011,2010,2009,2008,2007,2006,2005

America's Top Oncologists 2007


Dr. Sato also specializes in Cancer Immunotherapy.


  • Jichi Medical University, Japan, Medical School


  • Oita Prefectural Hospital, Japan


  • Jichi Medical University, Japan

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls

PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases

Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer

Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma

Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment

Immune check point inhibitors combination in melanoma: Worth the toxicity?

Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T)

Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization

Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography

Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells

Successes and setbacks of early investigational drugs for melanoma

Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma

Biology of advanced uveal melanoma and next steps for clinical therapeutics

Uveal melanoma metastatic to the liver: Chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea